News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Job Trends
Monsanto Company Sale of Posilac Leaves 280 Workers in Limbo
August 18, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Monsanto Co.'s decision to sell its Posilac business, which makes an artificial growth hormone for dairy cows, means an uncertain future for the approximately 280 Posilac employees, including 40 in St. Louis.
Twitter
LinkedIn
Facebook
Email
Print
Job creations
MORE ON THIS TOPIC
Layoff Tracker
Biogen Upends 20 Employees After Axing AAV Work
September 30, 2025
·
207 min read
·
BioSpace Editorial Staff
Job Trends
6 Companies Hiring Now in Pennsylvania
September 25, 2025
·
1 min read
·
Angela Gabriel
Job Trends
$100,000 H-1B Fee Leaves Biopharma Grappling With Impact
September 25, 2025
·
6 min read
·
Angela Gabriel
Job Trends
Talent Acquisition Leaders Reframe Recruiting, Focus On Internal Mobility
September 24, 2025
·
3 min read
·
Chantal Dresner